<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is defined by the presence of <z:mp ids='MP_0005048'>thrombosis</z:mp> and/or pregnancy morbidity in combination with the persistent presence of circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>: <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibodies and/or anti-Î²2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies in medium to high titers </plain></SENT>
<SENT sid="1" pm="."><plain>The management of <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with APS is a subject of controversy </plain></SENT>
<SENT sid="2" pm="."><plain>This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Rheumatology and Internal Medicine, with a clinical and research focus on APS </plain></SENT>
</text></document>